Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, and its prevalence has increased by 25% in the general population especially since the Covid19 outbreak. Hence, acceleration of the development of NASH therapeutic drugs by regulators.
Obeticholic acid is the only drug with significant benefit in the phase 3 interim results and remains the candidate for first conditional approval as a NASH therapeutic. However, monotherapy with these drugs leads to a histological resolution of NASH in less than one-third of patients in recent trials. Therefore, the future of NASH therapy will putatively be a combination therapy of two different drug classes with complementary effects. (1)
Mild to moderate fatty liver multidisciplinary rehabilitation combo (1-month trial)
Significant progress: about 2-3 months.
Multidisciplinary rehabilitation program
Please follow doctor's advice on drugs and other medical plans.
Please follow dietitian's guidelines for diet and nutrition.
For sports and or psychological counseling, please refer to experts' suggestions.
To avoid misdiagnosis or incorrect diagnosis, please upload medical report/s by professional bodies dated within a month.
Not suitable for these conditions:
Hepatic fibrosis and sclerosis
Alcoholic fatty liver
Allergic to the ingredients of the combination
Gastric ulcer
Suggested combination of supplements: (1-month trial)
Intake of minerals supplementation such as calcium and iron is not suitable
Go to bed early and get up early; don't stay up late
No less than 10000 steps of medium speed walking every day
Diet recommendations:
Try to eat less fried and roasted food
Do not eat high iron foods such as animal liver and blood
Caution:
Product/s is categorized as nutritional supplement and cannot replace drugs.
Not suitable for pregnant or lactating women, infants and young children.
If you do not know the cause of your health condition or the problem continues, please consult your doctor as soon as possible.
If you have a medical condition, please follow your doctor's medical treatment plan. Do consult your medical doctor before using the Multidisciplinary Rehabilitation Program (MRP). Please do not proceed if your medical doctor does not recommend the use of our MRP. If you'd like to seek a second opinion from other doctors, you may contact our online "Doctors Without Border", or other professional doctors at your convenience.
__
Ref / 參考文獻:
An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy. Monika Rau &Andreas Geier. https://doi.org/10.1080/17512433.2021.1884068
This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.
